- Active not recruitingPHASE2, PHASE3
Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency
This study is testing a new medicine called AT-007 for people with a genetic condition that affects their nerves, called SORD deficiency. Researchers want to see if AT-007 is safe and helps improve symptoms or slows the condition's progression.
For: Hereditary Neuropathy Caused by SORD DeficiencyUnited States · Czechia · Italy - Ongoing, recruitingPhase II and Phase III (Integrated)
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients with SoRbitol Dehydrogenase (SORD) DEficiency
This study looks into a new medicine called AT-007 for people with SORD Deficiency. It compares AT-007 to a dummy medicine to see if it lowers sorbitol levels in the blood and improves how people walk and function over 1 to 2 years.
For: Sorbitol Dehydrogenase (SORD) DeficiencyCzechia · Italy